医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmaron Earns CFDA GLP Certification for Toxicology Facility

2014年03月04日 AM09:25
このエントリーをはてなブックマークに追加


 

BEIJING

Pharmaron announced today that the company’s GLP toxicology facilities in Beijing have earned a certificate of full GLP compliance from the Chinese Food and Drug Administration (CFDA) based upon a thorough inspection of its facilities, operating procedures and technical competency of the staff. Pharmaron is currently under contract with Sponsors wishing to file INDs in China as the result of this news.

“This certification by the CFDA is a reflection of Pharmaron’s commitment to fully comply with the CFDA’s GLP standards. It provides another avenue for our Sponsors to submit regulatory data from our facilities. Pharmaron is well positioned today to provide toxicology and regulatory expertise to our customers intending to include the China market in their drug development strategy,” commented Pharmaron Chairman and CEO, Dr. Boliang Lou.

Pharmaron has a long-standing track record of performing acute and chronic GLP toxicology in China for U.S. and international Sponsors wishing to file INDs with the U.S. FDA. Addition of the CFDA-certified designation further secures Pharmaron’s leading position in GLP toxicology in China and strengthens its integrated and IND-enabling service capability and capacity that provides a custom-designed, project management team to move compounds from discovery chemistry and DMPK through GLP toxicology and IND support.

About Pharmaron

Pharmaron is a premier R&D service provider for the pharmaceutical and biotech industries. Founded in 2003, Pharmaron invests in its people and facilities enabling the Company to provide high quality R&D service across a number of disciplines, including chemistry, biology, DMPK, pharmacology, safety assessment, chemical and pharmaceutical development.

Pharmaron is steadily growing to meet the needs of its partners. With more than 2,000 employees and operations in China and the U.S., Pharmaron delivers superior scientific services while maintaining close communication with partners.

Pharmaron’s mission is to provide the highest quality drug R&D services, helping our partners advance their projects in a timely and cost effective manner. More information is available at www.pharmaron.com.

CONTACT

Pharmaron
Katherine Lee
Sr. VP, Strategic Partnership
562-686-9786
bd@pharmaron.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402